Anavex announces first entire clinical gene pathway data of ANAVEX 2-73

Anavex Life Sciences announced the first entire clinical gene pathway data from the ANAVEX2-73-RS-002 AVATAR Rett syndrome trial. ANAVEX2-73 transcriptomics analysis identified gene networks that are differentially expressed in Rett syndrome patients treated with ANAVEX2-73 compared to placebo. Patient samples that were analyzed contained on average over 20 million unique reads in both placebo and ANAVEX2-73 treated patients. Biological relevance of this pool of genes was assessed through pathway analysis and confirmed the impact of ANAVEX2-73 treatment on pathways involved in neurodevelopmental diseases. Christopher Missling, PhD, President and Chief Executive Officer of Anavex, stated, “We believe, this represents an extensive transcriptomics analysis of a therapeutic agent in patients with Rett syndrome and it is very exciting to witness ANAVEX2-73’s demonstration of its platform Precision Medicine potential for Rett syndrome with ability to compensate for expression levels of dysregulated developmental and metabolic genes, apparent within the Rett syndrome pathology. We are steadily making progress to learn more about this debilitating disorder and further analysis will be dedicated to evaluating the significance of each identified gene and gene variant and should deepen the understanding of the underlying signaling pathways involved in response to ANAVEX2-73 treatment in patients with Rett syndrome.”